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Abstract
Moss-aGalactosidase A (moss-aGal) is a moss-derived version of human
α-galactosidase developed for enzyme replacement therapy in patients with Fabry
disease. It exhibits a homogenous N-glycosylation profile with >90% mannose-
terminated glycans. In contrast to mammalian cell produced α-galactosidase,
moss-aGal does not rely on mannose-6-phosphate receptor mediated endocytosis
but targets the mannose receptor for tissue uptake. We conducted a phase 1 clinical
trial with moss-aGal in six patients with confirmed diagnosis of Fabry disease dur-
ing a 28-day schedule. All patients received a single dose of 0.2 mg/kg moss-aGal
by i.v.-infusion. Primary endpoints of the trial were safety and pharmacokinetics;
secondary endpoints were pharmacodynamics by analyzing urine and plasma Gb3
and lyso-Gb3 concentrations. In all patients, the administered single dose was well
tolerated. No safety issues were observed. Pharmacokinetic data revealed a stable
nonlinear profile with a short plasma half-life of moss-aGal of 14 minutes. After
one single dose of moss-aGal, urinary Gb3 concentrations decreased up to 23%
7 days and up to 60% 28 days post-dose. Plasma concentrations of lyso-Gb3
decreased by 3.8% and of Gb3 by 11% 28 days post-dose. These data reveal that a
single dose of moss-aGal was safe, well tolerated, and led to a prolonged reduction
of Gb3 excretion. As previously shown, moss-aGal is taken up via the mannose
receptor, which is expressed on macrophages but also on endothelial and kidney
cells. Thus, these data indicate that moss-aGal may target kidney cells. After these
promising results, phase 2/3 clinical trials are in preparation.
KEYWORD S
Agalsidase, alpha-galactosidase, Fabry disease, mannose receptor, moss, Physcomitrella
1 | INTRODUCTION
Fabry disease (FD) (Online Mendelian Inheritance in Man
301500) is an X-linked progressive multi-organ disease
caused by mutations in the GLA gene. These mutations
result in decreased or deficient levels of the lysosomal
enzyme α-galactosidase A (EC 3.2.1.22), thus leading to
accumulation of globotriaosylceramide (Gb3) and related
glycosphingolipids in many cell types, for example, vascular
endothelial cells, podocytes, and cardiomyocytes. The
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affection of vascular endothelial cells results in a vasculopa-
thy of small vessels, mainly in kidney, heart, and central ner-
vous system. The prevalence in hemizygous male FD-
patients is estimated at 1 in 40 000. Heterozygous female
carriers are also affected by the disease. The clinical picture
is broad and symptoms progress with increasing age. Typi-
cal clinical symptoms include neuropathic pain, hypohidro-
sis, angiokeratoma, cornea verticillata, diarrhea, chronic
kidney disease, cardiomyopathy, arrhythmia, and stroke.1
Specific treatment for FD consists either of enzyme
replacement therapy (ERT) or chaperone therapy, mainly in
reducing storage material in the endothelial cells of different
organs. Early start of treatment results in a reduction of life-
threatening events. In Europe, two different ERTs for
biweekly i.v.-application are approved: Agalsidase alfa and
Agalsidase beta.2 Since 2016, a chaperone therapy with
Migalastat is approved in patients with FD aged 16 years
and older who are carrying certain amenable mutations.3
Cellular uptake of mammalian cell produced
α-galactosidase occurs mainly via mannose-6-phosphate
(M6P) receptor mediated endocytosis.4 However, there is
increasing evidence for additional alternative uptake routes of
which the mannose receptor (MR) is a promising example.5,6
MR recognizes terminal mannose, fucose, and N-
acetylglucosamine residues of glycoproteins and is expressed
in dendritic, endothelial, smooth muscle, and renal mesangial
cells.7 Due to this expression pattern, MR is an interesting
new target for a potentially improved FD therapy. Moss-aGal
is produced in the moss Physcomitrella patens and exhibits a
very homogenous glycosylation profile with exclusively man-
nose or N-acetylglucosamine residues targeting MR.6 Poten-
tially immunogenic plant specific xylose and fucose residues
have been eliminated through genetic engineering.8
Previous in vitro and in vivo testing of moss-aGal con-
firmed its efficient uptake and its ability to degrade accumu-
lated Gb3 in the target organs kidney and heart.6 Results
from the murine FD model suggested that the MR pathway
might play an important role targeting Agalsidase into the
kidney.6
The here presented data of the first human clinical trial
demonstrates the safety of a single dose of moss-aGal and
represents the first step for a full clinical development of
moss-aGal as a new therapeutic option for FD.
2 | MATERIALS AND METHODS
2.1 | Moss-aGal
Human alpha-galactosidase was produced in the moss Phys-
comitrella patens as described previously.6 The study drug
was manufactured, tested, and released by Glycotope Bio-
technology GmbH (Heidelberg, Germany), according to
Good Manufacturing Practice and local regulations. Moss-
aGal preparations were provided in 10 mL glass vials with
5 mL aqueous solution for infusion at a concentration
0.35 mg/mL.
2.2 | Study design
The trial was designed as an open-label, single-arm, phase 1
study in patients with Fabry disease with sequential adminis-
tration of one dose of moss-aGal. Eligible patients received
a single dose of 0.2 mg/kg body weight moss-aGal over an
infusion period of 60 ± 5 minutes on day 1. Total infusion
volume was 250 mL. For safety reasons, patients were hos-
pitalized during the infusion and at least until 24 hours after
end of the infusion. Follow-up visits were scheduled on days
2, 7, 14, and 28. A total of six patients were planned to be
enrolled. Treatment occurred sequentially.
Primary endpoints of the trial were safety and evaluation
of pharmacokinetics. Secondary endpoint was the evaluation
of pharmacodynamics by analyses of Gb3 and globotriaosyl-
sphingosine (lyso-Gb3) concentrations in plasma and urine.
Inclusion criteria were female or male patients aged
18-65 years with confirmed diagnosis of FD, either by con-
firmation of deficient α-Gal A activity or by confirmation of
a disease-causing mutation in the GLA gene, which was
mandatory for women. Patients had to be treatment naïve or
paused ERT for at least 3 months. Only patients with ele-
vated plasma lyso-Gb3 concentrations were enrolled.
Patients had to present at least one clinical manifestation of
FD, for example, neuropathic pain, angiokeratoma, cornea
verticillata, cardiomyopathy, hypo- or anhydrosis, abdomi-
nal pain, diarrhea, serum creatinine >1.0 mg/dL, or protein-
uria >300 mg/24 hours. Patients of childbearing age or with
partners of childbearing age had to use a medically accept-
able method of contraception. All patients gave written
informed consent.
Patients with increased anti-α-Gal A immunoglobulin G
(IgG) concentrations at screening, known allergy, or intoler-
abilities to ERT, kidney disease requiring dialysis or a kid-
ney transplant, malignancies, or other severe diseases were
excluded.
This study was conducted in compliance with the ethical
principles originating in or derived from the Declaration of
Helsinki and in compliance with the institutional review
board, informed consent regulations, and International Con-
ference on Harmonization Good Clinical Practices Guide-
lines. All local regulatory requirements were followed. The
study was approved by the Ethics Committee of the State
Chamber of Medicine in Rhineland-Palatinate and the Ethics
Committee for Clinical Pharmacology KFEB, Budapest.
This clinical study has been registered in clinicaltrials.gov
(NCT02995993).
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2.3 | Statistical methods
Due to the small number of patients, only descriptive statisti-
cal analysis was performed. Analyses included all patients
that received an infusion of moss-aGal. Pharmacokinetic
variables were evaluated using standard noncompartmental
analyses and were descriptively summarized using spaghetti
plots. Gb3 and lyso-Gb3 concentrations were described as
change from baseline using box-plots for visualization (plot-
ting minimum, maximum, 1st and 3rd quartile, median).
2.4 | Safety assessment
Safety was assessed by evaluation of adverse events, physi-
cal examination, vital signs, 12-lead electrocardiography,
routine laboratory tests (hematology, coagulation tests, clini-
cal chemistry, and urine analysis), urine pregnancy test for
female patients of childbearing potential, and anti-aGal IgG
antibodies.
2.5 | Measurement of anti-alpha-galactosidase
antibodies
Measurement of anti-aGal IgG antibodies was performed by
enzyme-linked immunosorbent assay as previously described.9
Limit of detection was 6.25 antigen units (AU)/mL, but cross-
reaction with other antibodies were only excluded at titers
>20 AU/mL. Antibodies were determined at screening and
28 days. Analyses were performed by Prof. Dr. K. J. Lackner
and Dr. K. Bruns, Central Lab of the University Medical
Center Mainz.
2.6 | Quality of life and brief pain inventory
Quality of life was assessed by the 36-item Short Form Health
Survey questionnaire (SF36; Quality metrics). Levels of pain
over the past 24 hours were assessed by using the validated
Brief Pain Inventory (BPI).10 For method details and results
see Supplementary Tables S1-S2, Supporting Information.
2.7 | Measurement of Gb3- and lyso-
Gb3-concentrations
Gb3 was measured by liquid chromatography-mass spec-
trometry and tandem mass spectrometry (LC-MS/MS) in
plasma and morning urine at screening, baseline, day 7, 14,
and 28; lyso-Gb3 was measured by LC-MS/MS in plasma at
screening, baseline, day 7, 14, and 28. Plasma and urinary
concentrations of Gb3 isoforms Gb3-C24-0, Gb3-C16-0,
Gb3-C18-0, Gb3-C24-1 as well as lyso-Gb3 concentrations
in plasma were measured as described before.11,12
2.8 | Pharmakokinetics
Moss-aGal serum concentrations were determined by vali-
dated enzyme activity assay using 4-methylumbelliferyl
alpha-D-galactopyranoside as artificial substrate. The assay
was validated for moss-aGal serum concentrations in the
range 50-50 000 ng/mL. Serum for pharmacokinetic ana-
lyses was taken before start of the infusion, 55 minutes after
start of infusion, and 15 minutes, 30 minutes, 1, 2, 4, 8, and
24 hours post infusion.
3 | RESULTS
3.1 | Patient population
Nine patients (8 females, 1 male) were screened of whom
two did not meet the inclusion/exclusion criteria; one patient
withdrew its consent. The remaining six patients were eligi-
ble for study participation and were included in the study.
Patients included in the study were all females of Caucasian
origin with a median age of 50.5 years (range 38-59). Geno-
type of these patients is included in Supplementary
Table S3. Four patients were recruited from the study center
in Mainz, two from the center in Budapest.
3.2 | Dosing and adverse events
During the trial, no serious adverse events were observed. In
total, five adverse events (AEs) in four patients were
reported (Table 1). Only one AE, dysgeusia, was considered
being possibly related to the study medication. Headache
was the only AE considered to be an infusion-associated
reaction. Both events resolved within 24 hours. No patient
early terminated the trial.
3.3 | Clinical examination and laboratory
evaluation
There were no clinically relevant abnormal physical findings
and no clinically relevant changes of vital parameters. No
relevant changes in laboratory parameters were observed
TABLE 1 Overview of all adverse events (AEs)
Adverse event # of AEs (N)
# Of patients
with AEs (N)
Vulvitis 1 1
Limb discomfort 1 1
Dysgeusia 1 1
Headache 1 1
Oropharyngeal pain 1 1
Total 5 4
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after administration of the study drug. Urine pregnancy tests
were negative in all female patients before administration of
moss-aGal. No relevant changes were seen in electrocardio-
gram analyses.
3.4 | Formation of anti-aGal antibodies
All patients were negative for anti-aGal IgG antibodies at
screening and at close out visit on day 28. In one patient
anti-aGal antibody concentration was slightly elevated up to
7.4 AU/mL and did not change 28 days after a single dose
of moss-aGal. However, these concentrations remained
below the defined threshold of 20 AU/mL, at which unspe-
cific cross reactions of other antibodies can be excluded.
4 | PHARMACOKINETICS AND
PHARMACODYNAMICS
4.1 | Pharmacokinetic
Measurement of pharmacokinetic revealed a nonlinear stable
profile in all six patients (Figure 1). The maximum observed
serum concentration (C max) of moss-aGal was reached
55 minutes after start of the infusion, with a mean maximum
concentration of 946 ng/mL. Maximum concentrations
dropped to half the levels (t½) within 14 minutes (range
11-15 minutes). The mean steady state volume of distribu-
tion (Vss) was 0.13 L/kg and the apparent terminal volume
of distribution (Vz) was at 0.08 L/kg slightly smaller.
Table 2 summarizes the main pharmacokinetic parameters.
4.2 | Plasma Gb3 and lyso-Gb3 concentrations
Before treatment, all patients had elevated plasma concentra-
tions of lyso-Gb3 with a median of 5.25 ng/mL (range
1.43-12.00). After one single dose of moss-aGal, median
lyso-Gb3 plasma concentrations decreased by 3.77% from
baseline to day 28 (Supplementary Figure S1). Plasma Gb3
(Gb3-C24-0) concentrations decreased from baseline to day
28, with a median decrease of 11% (Figure 2A). Other Gb3
isoforms also showed a slight decrease in plasma with a
median decrease of 7.2% for Gb3-C16-0, 4.9% for
Gb3-C18-0, and 0.8% for Gb3-C24-1 (Supplementary
Figure S2).
4.3 | Urine Gb3 concentrations
After one single dose of moss-aGal, Gb3 in morning urine
decreased continuously in all patients from baseline to day
28. The mean decrease from baseline of urinary Gb3
(Gb3-C24-0) was 23% at day 7, 54% at day 14, and 60% at
day 28 post-dose (Figure 2B). Urinary Gb3-C24-0 concen-
trations showed the largest decrease but urinary Gb3-C16-0,
Gb3-C18-0, and Gb3-C24-1 concentrations also decreased
from baseline to day 28 (Supplementary Figure S3).
5 | DISCUSSION
This is the first clinical trial with moss derived human alfa
galactosidase in humans with FD, and the first trial ever with
FIGURE 1 Serum concentration of moss-aGal after i.v.-infusion.
Serum concentrations of moss-aGal were measured at indicated time
points using a validated enzyme activity assay
TABLE 2 Overview of pharmacokinetic parameters
Cmax
(ng/mL)
tmax
(h)
AUClast
(h ng/mL)
AUC0-inf
(h ng/mL)
t1/2
(h)
MRT
(h)
CL
(L/h/kg)
VZ
(L/kg)
VSS
(L/kg)
N 6 6 6 5 5 5 5 5 5
Mean 946 0.92 789 789 0.23 0.51 0.26 0.08 0.13
Minimum 840 0.92 677 720 0.18 0.49 0.21 0.07 0.12
Median 965 0.92 738 747 0.23 0.51 0.27 0.08 0.13
Maximum 1049 0.92 970 937 0.25 0.56 0.28 0.10 0.14
Abbreviations: AUC0−inf, area under the serum concentration curve (AUC) extrapolated to infinity; AUClast, AUC between the time of dosing and the last measurable
(positive) concentration; Cmax, maximum observed serum concentration; CL, total serum clearance; MRT, main residence time extrapolated to infinity; t1/2, terminal
elimination half-life; tmax, time to Cmax; Vz, apparent terminal volume of distribution; VSS, steady state volume of distribution.
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a biological drug manufactured in moss. It demonstrates the
tolerability of a single administration of moss-aGal.
The moss system is used for the production of a variety
of different recombinant proteins, as different growth factors
and complement factor H.13 The application of a moss-derived
protein on humans is possible as the basic structures of N-
glycosylation are conserved between humans and plants.
However, in contrast to mammalian cell produced
α-galactosidase charges, which show a heterogeneous glyco-
sylation profile with 25-40% of phosphorylated carbohydrate
residues, moss-aGal has a more homogenous glycosylation
profile with exclusively mannose and N-acetylglucosamine
terminated glycans.6,14 Thus, moss-aGal is not endocytosed
by M6P receptors but targets the MR for tissue uptake. It
has been shown that the expression of MR is not only
restricted to macrophages, but that MR are also expressed on
a variety of different cell types, such as endothelial, kidney
mesangial, dendritic, tracheal smooth muscle, and retinal
pigment epithelium cells.7
5.1 | Safety
A single administration of moss-aGal revealed a good safety
profile as it was tolerated without any severe adverse events.
Headache as an adverse event was evaluated as potentially
infusion related and has been reported as ERT-related before.15
The adverse event of dysgeusia was evaluated as possibly
drug-related and has never been reported before on ERT in
FD. However, further clinical studies are required to evaluate
the safety profile of moss-aGal upon repeated administration.
5.2 | Antibodies
None of the patients developed anti-aGal IgG antibodies
after one single dose of moss-aGal. This result was expected
since formation of IgG antibodies against Agalsidase alfa
and beta mainly affects male patients and requires repeated
exposure to Agalsidase. In the majority of patients, anti-
bodies develop during the first 3 months of ERT.16 The
slightly elevated anti-aGal antibody concentration in one
patient did not alter after application of moss-aGal, and,
thus, was interpreted as an unspecific cross-reaction. The
immunogenicity profile of moss-aGal will be evaluated in an
upcoming phases 2-3 clinical trial which will involve male
patients and a repeated dosing over at least 6 months.
5.3 | Pharmacokinetics
Data on pharmacokinetics demonstrated a stable profile in
all patients with a short plasma half-life of the infused
enzyme of only 14 minutes. In contrast, mammalian cell
produced α-galactosidase charges have a much longer
plasma half-life time: plasma half-life of Agalsidase alfa is
108 ± 17 minutes in males and 89 ± 28 minutes in
females,17 of Agalsidase beta 80-120 minutes.18
A potential sink for moss-aGal is the uptake of the
enzyme by macrophages which express mannose receptors,
as it has been demonstrated for mannose terminating gluco-
cerebrosidase.19 However, the prolonged decrease in urinary
Gb3 concentrations even 28 days after a single dose of
moss-aGal is an indication for targeting of the kidney, espe-
cially as the reduction of Gb3 concentrations was much
higher in urine as in blood. The assumption that macro-
phages are not the only sink for moss-aGal is supported by
previous in vitro and in vivo studies. In the mouse model,
moss-aGal and Agalsidase alfa had comparable efficacy in
FIGURE 2 Relative change to baseline of Gb3 concentrations in
plasma (A) and urine (B) after moss-aGal dosing. Shown are Gb3
(Gb3-C24-0 isoform) concentrations. For urinary values, Gb3 levels
were measured at indicated time points and related to urinary creatinine
level. Length of the box represents the interquartile range (25th and
75th percentile). The line represents the median and the cross the mean.
Whiskers show minimum to maximum values
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reducing Gb3 concentrations in the kidney, reflecting a simi-
lar effectiveness of cellular uptake in this organ.6 As previ-
ously shown by in vitro and in vivo experiments, moss-aGal
has a higher uptake in cultured endothelial cells than Agalsi-
dase alfa.6 Thus, the short plasma half-life of moss-aGal
may be a combination of uptake by macrophages and endo-
thelial cells via the MR.
5.4 | Pharmacodynamics
Regarding plasma substrate degradation, after one single
dose of moss-aGal no relevant changes in plasma Gb3 and
lyso-Gb3 concentrations were found. Plasma Gb3 and lyso-
Gb3 concentrations were measured at baseline and only
7 days after the application of moss-aGal. Thus, a decrease
of these metabolites in plasma might have occurred shortly
after the application of moss-aGal and might have been
missed due to the long time-period of 7 days between appli-
cation and determination. However, in consecutive trials,
plasma Gb3 and lyso-Gb3 concentrations should be deter-
mined already within 24 hours application of moss-aGal.
The decrease of urinary Gb3 excretion after one single
dose of moss-aGal demonstrates that moss-aGal targets the
kidney and is enzymatically active. The prolonged decrease
of Gb3 excretion seems to reflect a long half-life of the
enzyme in the renal cells and a slow turnover of tubular
cells.20 These may lead to a continuous substrate degrada-
tion resulting in a prolonged reduction of urinary Gb3 excre-
tion. The effect of moss-aGal on urinary Gb3 excretion was
much higher than previously reported for mammalian cell
produced α-galactosidase.20
After these promising results, phase 2/3 clinical trials are
in preparation.
6 | CONCLUSION
In conclusion, these data sustain the hypothesis that
mannose-terminated enzymes may be effective also in lyso-
somal storage disorders in which nonmacrophage cells are
mainly affected. This study demonstrated that a single infusion
of moss-aGal was safe, well tolerated and led to a prolonged
reduction of urinary Gb3 excretion.
After these promising results, phase 2/3 clinical trials for
moss-aGal are in preparation.
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